NDABUCCALFILM, EXTENDED RELEASE
Approved
May 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
DENTIPATCH (lidocaine) by Noven Pharmaceuticals is clinical pharmacology mechanism of action: lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. First approved in 1996.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DENTIPATCH is a lidocaine 5% buccal film for topical local anesthesia with a 3-5 minute onset of action. Lidocaine stabilizes neuronal membranes by inhibiting ionic fluxes required for impulse initiation and conduction, producing local anesthetic effects. It is indicated for patients requiring rapid, localized pain relief in the oral cavity.
LOE Approaching
As LOE approaches, brand teams are transitioning from growth to defensive strategies; team size and budgets may shift toward lifecycle extension or be consolidated.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of action: Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Onset of anesthesia: Lidocaine Ointment 5% effects local, topical anesthesia. The…
Worked on DENTIPATCH at Noven Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.